Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -22.14M | -26.28M | -23.25M | -29.98M | -29.22M |
| Total Depreciation and Amortization | 1.54M | 1.51M | 1.46M | 1.45M | 1.26M |
| Total Amortization of Deferred Charges | 45.00K | -238.00K | -46.00K | 247.00K | 432.00K |
| Total Other Non-Cash Items | 2.57M | 2.01M | -2.02M | 4.91M | 6.79M |
| Change in Net Operating Assets | -1.70M | 3.54M | -4.17M | -4.34M | -6.24M |
| Cash from Operations | -19.69M | -19.46M | -28.03M | -27.71M | -26.98M |
| Capital Expenditure | -16.00K | -81.00K | -147.00K | -453.00K | -585.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | 9.00K | 9.00K | 9.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 35.00K | 35.00K | 98.00K | 98.00K |
| Cash from Investing | -16.00K | -46.00K | -103.00K | -346.00K | -478.00K |
| Total Debt Issued | 3.80M | 3.80M | 3.20M | 4.10M | 3.25M |
| Total Debt Repaid | -1.88M | -4.16M | -4.16M | -2.36M | -2.35M |
| Issuance of Common Stock | 22.87M | 9.24M | 5.56M | 100.00K | 281.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 19.35M | 24.50M | 24.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.58M | 2.42M | 2.95M | 1.92M | 3.37M |
| Cash from Financing | 27.37M | 11.30M | 26.89M | 28.27M | 29.04M |
| Foreign Exchange rate Adjustments | -13.00K | -48.00K | 8.00K | 11.00K | -6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.64M | -8.25M | -1.23M | 224.00K | 1.58M |